SlideShare a Scribd company logo
1 of 29
Hypothalamic and Pituitary 
Agents 
Chapter 35 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Endocrine System 
• Main function is to maintain homeostasis 
• Too much or too little glandular activity 
– Disrupts homeostasis 
– Leads to various disorders 
– Interferes with the normal functioning of other 
endocrine glands 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Hypothalamic Releasing Factors With 
Diagnostic Functions 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• CRH 
– Stimulates release of ACTH from anterior pituitary 
– Used to diagnose Cushing’s disease 
• Gonadorelin (Factrel) 
– GnRH analog 
– Checks for anterior pituitary response and 
gonadotropin deficiency
Hypothalamic Releasing Factors With 
Diagnostic Functions (cont.) 
• TRH (Protirelin) 
– Stimulates the pituitary to produce thyrotropin, 
which stimulates the thyroid to produce thyroid 
hormones 
• GHRH (Sermorelin) 
– Stimulates the production of growth hormone (GH) 
by the anterior pituitary 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Hypothalamic Releasing Factors Used to 
Treat Diseases and Their Actions 
• Goserelin (Zoladex) 
– Analog of GnRH; inhibits pituitary gonadotropin 
secretion with a resultant drop in the production of 
the sex hormones 
• Histrelin (Supprelin), Ganirelix (Antagon), and Abarelix 
(Plenaxis) 
– GnRH agonists; inhibits gonadotropin secretion and 
decrease the levels of steroid sex hormones 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Hypothalamic Releasing Factors Used to 
Treat Diseases and Their Actions (cont.) 
• Leuprolide (Lupron) 
– Occupies pituitary GnRH receptor sites so that they 
no longer respond to GnRH 
• Nafarelin (Synarel) 
– A potent agonist of GnRH; decreases production of 
gonadal hormones by repeated stimulation of 
receptor sites 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Site of Action of Hypothalamic and 
Pituitary Agents 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Anterior Pituitary Hormones and Their 
Indications 
• Chorionic Gonadotropin (Chorex): Hypogonadism, 
ovulation, prepubertal cryptorchidism 
• Corticotropin (Acthar), or ACTH: Test adrenal function 
and responsiveness 
• Cosyntropin (Cortrosyn): Diagnose adrenal dysfunction 
• Menotropins (Pergonal): Fertility drug 
• Somatropin (Nutropin, etc.): Growth failure, Turner’s 
syndrome, AIDS, growth hormone deficiency 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Anterior Pituitary Hormones and Their 
Indications (cont.) 
• Somatropin rDNA origin (Zorbtive): Short bowel 
syndrome 
• Thyrotropin (Thytropar): Diagnostic agent to evaluate 
thyroid function 
• Somatrem (Protropin): Treat children with growth failure 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Anterior Pituitary Hormones 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Somatropin is a hormone of recombinant DNA origin 
that is equivalent to human growth hormone 
• Indications 
– Used in patients experiencing growth 
• Pharmacokinetics 
– Injected and reaches peak in 7 hours 
– Widely distributed in the body 
– Excreted through urine and feces
Anterior Pituitary Hormones (cont.) 
• Contraindications 
– Known allergy 
– Allergy to ingredients in the drug 
– Presence of closed epiphyses 
– Underlying cranial lesions 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Anterior Pituitary Hormones (cont.) 
• Adverse Reactions 
– Inflammation 
– Swelling and joint pain 
– Hypothyroidism and insulin resistance 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Question 
Please answer the following statement as true or false. 
Somatropin is a hormone of recombinant DNA origin that is 
equivalent to human growth hormone. 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Answer 
True 
Rationale: Somatropin replaces human growth hormone; 
stimulates skeletal growth, growth of internal organs, 
and protein synthesis. 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Growth Hormone Antagonists 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Is an inhibitory factor released from the 
hypothalamus 
– Not used to decrease GH 
– Has multiple effects on many of the secretory 
systems 
• Indications 
– Treatment of acromegaly 
• Pharmacokinetics 
– Varies depending on the drug
Growth Hormone Antagonists (cont.) 
• Contraindications 
– Known allergy 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Caution 
– Pregnancy or lactation 
– Presence of any other endocrine disorder 
• Adverse Reactions 
– Varies with each medication
Posterior Pituitary Hormones 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Indications 
– Treatment of neurogenic diabetes insipidus 
– Desmopressin is also indicated for the treatment of 
hemophilia A and von Willebrand’s disease 
– Nocturnal enuresis 
• Pharmacokinetics 
– Rapidly absorbed and metabolized 
– Excreted in the liver and kidneys 
– Not used during pregnancy due to the risk of uterine 
contractions
Posterior Pituitary Hormones (cont.) 
• Contraindications 
– Known allergy 
– Severe renal dysfunction 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Caution 
– Known vascular disease 
– Epilepsy 
– Asthma 
– Pregnancy 
– Lactation
Posterior Pituitary Hormones (cont.) 
• Adverse Reactions 
– Water intoxication 
• Related to the shift in water retention 
– Stimulation of GI tract 
– Local nasal irritation 
– Hypersensitivity 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Use of Hypothalamic and Pituitary Agents 
Across the Lifespan 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Hypothalamic Releasing Factors 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Hypothalamic Releasing Factors 
(Contiuned) 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Anterior Pituitary Hormones – 
Growth Hormone, Agonist 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Anterior Pituitary Hormones – 
Growth Hormone, Antagonist 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Anterior Pituitary Hormones – 
Growth Hormone, Antagonist (Continued) 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Anterior 
Pituitary Hormones – Growth Hormone 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Posterior 
Pituitary Hormones 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Question 
The nurse is caring for a 10-year-old boy with growth 
hormone deficiency. The child asks the nurse how long 
he will be able to take his medicine. Which of the 
following is best response? 
A. Until you decide to stop 
B. Until you are 13 
C. Until your epiphyseal plates close 
D. Until you get as tall as you want to be 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Answer 
C. Until your epiphyseal plates close 
Rationale: In normal growth and development growth 
ceases when the epiphyseal plates fuse to the ends of the 
long bones. 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

More Related Content

What's hot

What's hot (18)

Chapter039
Chapter039Chapter039
Chapter039
 
Ppt chapter 52-1
Ppt chapter 52-1Ppt chapter 52-1
Ppt chapter 52-1
 
Ppt chapter 33
Ppt chapter 33Ppt chapter 33
Ppt chapter 33
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40
 
Ppt chapter 21
Ppt chapter 21Ppt chapter 21
Ppt chapter 21
 
Ppt chapter 38-1
Ppt chapter 38-1Ppt chapter 38-1
Ppt chapter 38-1
 
Ppt chapter 56
Ppt chapter 56Ppt chapter 56
Ppt chapter 56
 
Chapter040
Chapter040Chapter040
Chapter040
 
Ppt chapter 34
Ppt chapter 34Ppt chapter 34
Ppt chapter 34
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20
 
Ppt chapter 19
Ppt chapter 19Ppt chapter 19
Ppt chapter 19
 
Ppt chapter 51
Ppt chapter 51Ppt chapter 51
Ppt chapter 51
 
Chapter032
Chapter032Chapter032
Chapter032
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37
 
Chapter031
Chapter031Chapter031
Chapter031
 
Ppt chapter 16-1
Ppt chapter 16-1Ppt chapter 16-1
Ppt chapter 16-1
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32
 

Viewers also liked

Viewers also liked (20)

Ppt08
Ppt08Ppt08
Ppt08
 
Ppt chapter 34-1
Ppt chapter 34-1Ppt chapter 34-1
Ppt chapter 34-1
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 
Ppt09 1
Ppt09 1Ppt09 1
Ppt09 1
 
Ppt chapter 17
Ppt chapter 17Ppt chapter 17
Ppt chapter 17
 
1 drugs acting on cardiovascular system
1 drugs acting on cardiovascular system1 drugs acting on cardiovascular system
1 drugs acting on cardiovascular system
 
Ppt chapter 35
Ppt chapter 35Ppt chapter 35
Ppt chapter 35
 
Diuretics
DiureticsDiuretics
Diuretics
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
 
Ppt chapter 18
Ppt chapter 18Ppt chapter 18
Ppt chapter 18
 
JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013
JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013
JNC VIII GUIDELINES FOR MANAGEMENT OF BLOOD PRESSURE 2013
 
Antipsychotic drugs
Antipsychotic drugsAntipsychotic drugs
Antipsychotic drugs
 
Cardiovascular drugs
Cardiovascular drugsCardiovascular drugs
Cardiovascular drugs
 
Diuretics
DiureticsDiuretics
Diuretics
 
Ppt chapter 51-1
Ppt chapter 51-1Ppt chapter 51-1
Ppt chapter 51-1
 
Diuretics2
Diuretics2Diuretics2
Diuretics2
 
Drugs affecting Cardiovascular system
Drugs affecting Cardiovascular systemDrugs affecting Cardiovascular system
Drugs affecting Cardiovascular system
 
Diuretics
DiureticsDiuretics
Diuretics
 
Structure activity relation ship
Structure activity relation shipStructure activity relation ship
Structure activity relation ship
 
Diuretics
DiureticsDiuretics
Diuretics
 

Similar to Ppt chapter 35-1

Ppt chapter 35
Ppt chapter 35Ppt chapter 35
Ppt chapter 35stanbridge
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59stanbridge
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37stanbridge
 
Ppt chapter 37-1
Ppt chapter 37-1Ppt chapter 37-1
Ppt chapter 37-1stanbridge
 
Ppt chapter 34
Ppt chapter 34Ppt chapter 34
Ppt chapter 34stanbridge
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52stanbridge
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36stanbridge
 
Ppt chapter 50
Ppt chapter 50Ppt chapter 50
Ppt chapter 50stanbridge
 
Ppt chapter 53-1
Ppt chapter 53-1Ppt chapter 53-1
Ppt chapter 53-1stanbridge
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16stanbridge
 
PPT_Chapter_22.ppt
PPT_Chapter_22.pptPPT_Chapter_22.ppt
PPT_Chapter_22.pptHillaryBell4
 
Ppt chapter 39
Ppt chapter 39Ppt chapter 39
Ppt chapter 39stanbridge
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52stanbridge
 
Ppt chapter 58
Ppt chapter 58Ppt chapter 58
Ppt chapter 58stanbridge
 
Ppt chapter 58
Ppt chapter 58Ppt chapter 58
Ppt chapter 58stanbridge
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48stanbridge
 
Ppt chapter 38
Ppt chapter 38Ppt chapter 38
Ppt chapter 38stanbridge
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36stanbridge
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48stanbridge
 

Similar to Ppt chapter 35-1 (20)

Ppt chapter 35
Ppt chapter 35Ppt chapter 35
Ppt chapter 35
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37
 
Ppt chapter 37-1
Ppt chapter 37-1Ppt chapter 37-1
Ppt chapter 37-1
 
Ppt chapter 34
Ppt chapter 34Ppt chapter 34
Ppt chapter 34
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36
 
Ppt chapter 50
Ppt chapter 50Ppt chapter 50
Ppt chapter 50
 
Ppt chapter 53-1
Ppt chapter 53-1Ppt chapter 53-1
Ppt chapter 53-1
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
 
PPT_Chapter_22.ppt
PPT_Chapter_22.pptPPT_Chapter_22.ppt
PPT_Chapter_22.ppt
 
Ppt chapter 39
Ppt chapter 39Ppt chapter 39
Ppt chapter 39
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52
 
Chapter031
Chapter031Chapter031
Chapter031
 
Ppt chapter 58
Ppt chapter 58Ppt chapter 58
Ppt chapter 58
 
Ppt chapter 58
Ppt chapter 58Ppt chapter 58
Ppt chapter 58
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 
Ppt chapter 38
Ppt chapter 38Ppt chapter 38
Ppt chapter 38
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 

More from stanbridge

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecturestanbridge
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2stanbridge
 
Creating a poster
Creating a posterCreating a poster
Creating a posterstanbridge
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Disseminationstanbridge
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5stanbridge
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4stanbridge
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors stanbridge
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learnerstanbridge
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policystanbridge
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentstanbridge
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005stanbridge
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007stanbridge
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006stanbridge
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004stanbridge
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009stanbridge
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008stanbridge
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21stanbridge
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22stanbridge
 

More from stanbridge (20)

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecture
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2
 
Creating a poster
Creating a posterCreating a poster
Creating a poster
 
Sample poster
Sample posterSample poster
Sample poster
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learner
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policy
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
 
Ot5101 week1
Ot5101 week1Ot5101 week1
Ot5101 week1
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22
 

Ppt chapter 35-1

  • 1. Hypothalamic and Pituitary Agents Chapter 35 Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 2. Endocrine System • Main function is to maintain homeostasis • Too much or too little glandular activity – Disrupts homeostasis – Leads to various disorders – Interferes with the normal functioning of other endocrine glands Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 3. Hypothalamic Releasing Factors With Diagnostic Functions Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • CRH – Stimulates release of ACTH from anterior pituitary – Used to diagnose Cushing’s disease • Gonadorelin (Factrel) – GnRH analog – Checks for anterior pituitary response and gonadotropin deficiency
  • 4. Hypothalamic Releasing Factors With Diagnostic Functions (cont.) • TRH (Protirelin) – Stimulates the pituitary to produce thyrotropin, which stimulates the thyroid to produce thyroid hormones • GHRH (Sermorelin) – Stimulates the production of growth hormone (GH) by the anterior pituitary Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 5. Hypothalamic Releasing Factors Used to Treat Diseases and Their Actions • Goserelin (Zoladex) – Analog of GnRH; inhibits pituitary gonadotropin secretion with a resultant drop in the production of the sex hormones • Histrelin (Supprelin), Ganirelix (Antagon), and Abarelix (Plenaxis) – GnRH agonists; inhibits gonadotropin secretion and decrease the levels of steroid sex hormones Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 6. Hypothalamic Releasing Factors Used to Treat Diseases and Their Actions (cont.) • Leuprolide (Lupron) – Occupies pituitary GnRH receptor sites so that they no longer respond to GnRH • Nafarelin (Synarel) – A potent agonist of GnRH; decreases production of gonadal hormones by repeated stimulation of receptor sites Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 7. Site of Action of Hypothalamic and Pituitary Agents Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 8. Anterior Pituitary Hormones and Their Indications • Chorionic Gonadotropin (Chorex): Hypogonadism, ovulation, prepubertal cryptorchidism • Corticotropin (Acthar), or ACTH: Test adrenal function and responsiveness • Cosyntropin (Cortrosyn): Diagnose adrenal dysfunction • Menotropins (Pergonal): Fertility drug • Somatropin (Nutropin, etc.): Growth failure, Turner’s syndrome, AIDS, growth hormone deficiency Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 9. Anterior Pituitary Hormones and Their Indications (cont.) • Somatropin rDNA origin (Zorbtive): Short bowel syndrome • Thyrotropin (Thytropar): Diagnostic agent to evaluate thyroid function • Somatrem (Protropin): Treat children with growth failure Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 10. Anterior Pituitary Hormones Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Somatropin is a hormone of recombinant DNA origin that is equivalent to human growth hormone • Indications – Used in patients experiencing growth • Pharmacokinetics – Injected and reaches peak in 7 hours – Widely distributed in the body – Excreted through urine and feces
  • 11. Anterior Pituitary Hormones (cont.) • Contraindications – Known allergy – Allergy to ingredients in the drug – Presence of closed epiphyses – Underlying cranial lesions Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 12. Anterior Pituitary Hormones (cont.) • Adverse Reactions – Inflammation – Swelling and joint pain – Hypothyroidism and insulin resistance Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 13. Question Please answer the following statement as true or false. Somatropin is a hormone of recombinant DNA origin that is equivalent to human growth hormone. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 14. Answer True Rationale: Somatropin replaces human growth hormone; stimulates skeletal growth, growth of internal organs, and protein synthesis. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 15. Growth Hormone Antagonists Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Is an inhibitory factor released from the hypothalamus – Not used to decrease GH – Has multiple effects on many of the secretory systems • Indications – Treatment of acromegaly • Pharmacokinetics – Varies depending on the drug
  • 16. Growth Hormone Antagonists (cont.) • Contraindications – Known allergy Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Caution – Pregnancy or lactation – Presence of any other endocrine disorder • Adverse Reactions – Varies with each medication
  • 17. Posterior Pituitary Hormones Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Indications – Treatment of neurogenic diabetes insipidus – Desmopressin is also indicated for the treatment of hemophilia A and von Willebrand’s disease – Nocturnal enuresis • Pharmacokinetics – Rapidly absorbed and metabolized – Excreted in the liver and kidneys – Not used during pregnancy due to the risk of uterine contractions
  • 18. Posterior Pituitary Hormones (cont.) • Contraindications – Known allergy – Severe renal dysfunction Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Caution – Known vascular disease – Epilepsy – Asthma – Pregnancy – Lactation
  • 19. Posterior Pituitary Hormones (cont.) • Adverse Reactions – Water intoxication • Related to the shift in water retention – Stimulation of GI tract – Local nasal irritation – Hypersensitivity Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 20. Use of Hypothalamic and Pituitary Agents Across the Lifespan Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 21. Prototype Hypothalamic Releasing Factors Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 22. Prototype Hypothalamic Releasing Factors (Contiuned) Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 23. Prototype Anterior Pituitary Hormones – Growth Hormone, Agonist Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 24. Prototype Anterior Pituitary Hormones – Growth Hormone, Antagonist Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 25. Prototype Anterior Pituitary Hormones – Growth Hormone, Antagonist (Continued) Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 26. Nursing Considerations for Anterior Pituitary Hormones – Growth Hormone • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 27. Nursing Considerations for Posterior Pituitary Hormones • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 28. Question The nurse is caring for a 10-year-old boy with growth hormone deficiency. The child asks the nurse how long he will be able to take his medicine. Which of the following is best response? A. Until you decide to stop B. Until you are 13 C. Until your epiphyseal plates close D. Until you get as tall as you want to be Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 29. Answer C. Until your epiphyseal plates close Rationale: In normal growth and development growth ceases when the epiphyseal plates fuse to the ends of the long bones. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins